Dementias Platform UK is a public-private partnership with links to organisations in the UK, Europe and further afield.
|Our academic partners||Our industry partners|
University of Cambridge
University of Edinburgh
Imperial College London
King's College London
University of Manchester
University of Newcastle
University of Oxford
University College London
Araclon Biotech S.L.
AstraZeneca Pharmaceuticals MedImmune Ltd
In addition to our partner organisations, DPUK scientists work with the following networks and initiatives across the world.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a public-private partnership increasing the pace of discovery in Alzheimer’s disease research. ADNI is designed to define biomarkers for use in clinical trials and to determine the best way to measure the treatment effects of AD therapeutics, including the use of biomarkers to detect AD at a pre-dementia stage.
Alzheimer’s Research UK is the world’s leading dementia research charity. The charity is backed by scientists and is dedicated to causes, diagnosis, prevention, treatment and cure.
Brains for Dementia Research was set up in 2007 to establish a network of brain bank facilities across England and Wales. In each bank, people with mild cognitive impairment or a diagnosis of dementia, and healthy participants, are supported to donate their brain by specialist research nurses.
The Canadian Consortium on Neurodegeneration in Aging (CCNA) provides the infrastructure and support that facilitates collaboration among Canada’s top dementia researchers. The CCNA is accelerating the discovery, innovation, and the adoption of new knowledge. This work will increase understanding of neurodegenerative diseases, and improve the quality of life of those living with dementia.
The Canadian Longitudinal Study on Aging (CLSA) is a large, national, long-term study that will follow approximately 50,000 men and women between the ages of 45 and 85 when recruited, for at least 20 years. The CLSA will collect information on the changing biological, medical, psychological, social, lifestyle and economic aspects of people’s lives. These factors will be studied to understand how they have an impact in both maintaining health and in the development of disease and disability as people age.
The UK Dementia Research Institute (DRI) is a joint £250 million investment into dementia research led by the Medical Research Council alongside Alzheimer’s Society and Alzheimer’s Research UK. The DRI brings together world-leading expertise in biomedical, care and translational dementia research in a national institute. The institute, made up of over 400 scientists, will carry out research relevant to all dementias.
The Dementia Research Funding Portal brings together funding opportunities from all the main UK research funders. The portal makes it easy for researchers to access the latest grant rounds, as well as news on relevant events and conferences.
Dementia UK provides specialist dementia support for families through its Admiral Nurse service. Admiral Nurses are continually trained, developed and supported by Dementia UK, so that families who receive support from Admiral Nurses have someone expert by their side, helping them to live more positively with dementia.
The European Medical Information Framework (EMIF) is a five year project that will develop common technical and governance solutions and improve access to human health data. This will help to improve life science research and bring better and safer medicine to patients. The EMIF project includes two specific therapeutic research topics: the onset of Alzheimer’s disease (EMIF-AD) and metabolic complications of obesity (EMIF-Metabolic).
The European Prevention of Alzheimer’s Dementia Consortium (EPAD) is bringing a more flexible approach to clinical trials of drugs designed to prevent dementia. EPAD is pioneering the use of adaptive trials in Alzheimer’s disease. With this approach, the project expects to be able to identify ineffective medicines earlier in drug development, which will help to avoid failures in more advanced trials.
The Global Alzheimer’s Association Interactive Network (GAAIN) is advancing research into the causes, prevention and treatment of Alzheimer's and other neurodegenerative diseases. The network provides a platform to unite a diverse and geographically distributed network of data partners to foster cohort discovery, collaboration and sharing. GAAIN is funded by the Alzheimer’s Association.
The Global Alzheimer's Platform Foundation (GAP) aims to drive solutions to the inefficiency and high risk of failure in Alzheimer’s clinical trials, speeding up the development path for over 100 AD therapies in development. It does this by bringing together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to reduce the time, cost and risk of Alzheimer’s clinical trials.
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative and aims to speed up the development of better and safer medicines for patients. A joint undertaking between the European Union and the EFPIA, the IMI supports collaborative research projects and builds networks of industrial and academic experts. The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments.
Join Dementia Research allows people to register their interest in participating in dementia research and be matched to suitable studies. Formed by the NIHR, Alzheimer Scotland, ARUK and Alzheimer’s Society, the service allows researchers and prospective study participants to connect.
The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to find cures for neurodegenerative diseases by increasing coordinated investment between participating countries. This will help to enable early diagnosis and identify appropriate ways to care for those with neurodegenerative diseases.
The National Institute for Health Research funds health and care research and translates discoveries into practical products, treatments, devices and procedures. They ensure the NHS is able to support the research of other funders to encourage broader investment in, and economic growth from, health research.
The NIHR Dementia Translational Research Collaboration (D-TRC) provides a network of world-leading investigators who are available to work with industry to further research and develop new treatments for dementia. They aim to carry out experimental medicine investigations focussing on biomarker discovery and validation, early diagnosis, patient stratification, phase I and phase II experimental medicine and proof of concept trials.
The overall aim of the Centres of Excellence in Neurodegeneration (CoEN) is to build collaborative research activity in neurodegeneration research across borders, focusing on the critical mass and excellence. The CoEN hosts calls for proposals for projects from Centres of Excellence. To date, it has initiated three calls for joint project proposals, resulting in 24 collaborative projects with awards totaling £12.3 m.
The mission of the Organisation for Economic Co-operation and Development (OECD) is to promote policies that will improve the economic and social well-being of people around the world. Working with governments to understand what drives economic, social and environmental change, they measure productivity and global flows of trade and investment. Using facts and real-life experience, the OECD recommends policies designed to improve the quality of people’s lives.
ROADMAPS (Real world outcomes across the Alzheimer’s disease spectrum for better care: multi-modal data access platform) provides the foundation for an integrated data environment and framework for real world evidence in Alzheimer’s disease. This includes guidelines on the handling and interpretation of data, development of consensual key outcome measures and data integration tools for dataset characterisation and outcome classification. ROADMAP has 22 partners and is led by the University of Oxford and Novartis.
The World Dementia Council (WDC) helps create a global environment in which societies, governments, industry, researchers and health and care systems all work together to transform the prospects for people affected by dementia in all its forms, so that the disease no longer negatively impacts on lives in the way it does today.